FDA Approved: TAFINLAR — Original Application (Novartis Pharmaceuticals Corporation)

View source ↗

Summary

FDA approved TAFINLAR (dabrafenib) under an Original Application for patients with unresectable or metastatic melanoma harboring a BRAF V600E mutation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Melanoma

Drugs mentioned

• TAFINLAR (DABRAFENIB)

Snippet

ORIG AP for TAFINLAR (DABRAFENIB)